Fioricet With Codeine

Quick links to important sections

Fioricet With Codeine

Selected form

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fioricet With Codeine

Property Description
Active Ingredients Butalbital, Acetaminophen, Caffeine, Codeine Phosphate
Form Capsule
Pharmacological Class Narcotic Analgesic Combination
General Purpose Relief of the symptom complex of tension headache
Origin Synthetic/Derived

What Type of Medicine is Fioricet With Codeine?

Fioricet With Codeine is a Fixed-Dose Combination Product, provided as a capsule for oral route administration, and is fundamentally classified as a Narcotic Analgesic Combination. This product is synthetic in origin, combining multiple chemically distinct active ingredients into a single formulation to achieve a synergistic effect. Its design represents a specialized treatment approach, which is clinically recognized for efficacy in cases where less potent, single-agent analgesics are insufficient.

The specific combination of agents, which includes both an opioid derivative, Codeine Phosphate, and a barbiturate derivative, Butalbital, differentiates it from non-combination products, confirming its designation as a Schedule III Controlled Substance.

What is Fioricet With Codeine Made Of?

The core of this medication is its blend of four active ingredients: Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate. Each component contributes a specific functional role to the overall profile. The inclusion of the barbiturate Butalbital, a CNS depressant, is a distinguishing characteristic of the formula, separating it from many other common opioid-containing analgesics, which primarily rely on non-opioid components.

The formula also incorporates Codeine Phosphate, an opioid agonist, alongside the non-opioid analgesic Acetaminophen and the CNS stimulant Caffeine. Combination analgesic products often achieve a broader level of relief compared to non-barbiturate combinations.

What is the General Purpose of This Combination Drug?

The general purpose of this medication is to provide comprehensive pain relief by simultaneously influencing pain signaling and associated physical tension. The product's mechanism utilizes the calming properties of Butalbital to ease muscular discomfort alongside the centralized pain-modifying effects of Codeine Phosphate and Acetaminophen. This multi-faceted approach aims to improve comfort through a synergistic effect of relaxation and increased pain tolerance, typically applied in cases involving the symptom complex of tension headache.

Regulatory References

  1. Butalbital, Acetaminophen, and Caffeine MedlinePlus Information

What side effects are possible with Fioricet With Codeine?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety risks for Fioricet With Codeine (Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate), strictly based on governmental regulatory documents.


Serious and Life-Threatening Risks

The medicine carries a Boxed Warning—the most serious regulatory warning—concerning several critical risks:

  • Addiction, Abuse, and Misuse potential, which can lead to overdose and death.
  • Life-Threatening Respiratory Depression (severe breathing problems), especially during treatment initiation or following a dose increase.
  • Hepatotoxicity (severe liver damage or failure) due to the acetaminophen component, particularly if the total daily dose is exceeded.
  • Risks from Concomitant Use with CNS Depressants (like alcohol or benzodiazepines), which can result in profound sedation, respiratory depression, coma, and death.
  • Neonatal Opioid Withdrawal Syndrome (NOWS) upon prolonged use during pregnancy.

Common Adverse Reactions

The following are frequently reported in regulatory documentation:

System-Organ Class Frequently Reported Reactions
Nervous System Drowsiness, lightheadedness, dizziness, sedation
Gastrointestinal Nausea, vomiting, abdominal pain
Other Shortness of breath, intoxicated feeling

Population-Specific Safety Restrictions

  • Contraindicated (forbidden) in all children younger than 12 years of age.
  • Contraindicated for use in children and adolescents under 18 years of age after surgery for tonsil or adenoid removal due to the risk of fatal breathing problems from codeine.
  • Use in lactating women is not recommended due to the risk of life-threatening side effects in the nursing infant related to codeine metabolism.

Regulatory Limitations

This medicine is classified as a Schedule III Controlled Substance ( C-III) due to the potential for dependence and abuse. The total daily intake of acetaminophen from all sources must not exceed 4000 milligrams to reduce the risk of hepatotoxicity.

Overdose and Emergency Response

The official regulatory profile for Fioricet With Codeine overdose is defined by the severe toxicities of its four components, necessitating immediate professional intervention for all suspected cases. The presence of Butalbital and Codeine dictates a high risk of central nervous system (CNS) and respiratory failure. Documented manifestations of overdose include profound sedation, confusion, slurred speech, and life-threatening respiratory depression, which can quickly escalate to coma and be fatal. Additional opioid toxicity signs, such as pinpoint pupils (miosis), hypotension, and blue skin (cyanosis), are documented.

A separate critical risk is associated with the Acetaminophen component: Acute Liver Failure. This severe outcome can occur even if initial overdose symptoms like nausea and abdominal pain are mild or absent. Due to this dual potential for CNS and hepatic damage, official labeling mandates seeking immediate medical attention for any suspected overdose or for accidental ingestion exceeding the maximum daily dose of Acetaminophen. The product is contraindicated in children younger than 12 years due to the high risk of fatal respiratory depression. Management procedures described in regulatory documents include close supportive care and the potential administration of two component-specific antidotes: Naloxone for opioid effects and N-acetylcysteine (NAC) for Acetaminophen toxicity.

Therapeutic Uses of Fioricet With Codeine

This combination product is commonly used in situations involving certain distressing symptoms. The medication is relevant for easing the symptom complex of tension headaches (or muscle contraction headaches), especially when non-opioid analgesic or alternative treatments have been inadequate.

The primary therapeutic domain is the management of the characteristic cluster of symptoms, including the head pain and the associated muscular tightness and physical discomfort. This approach is applied when short-term symptomatic assistance is needed for the acute episode. Its application is commonly considered relevant for individuals experiencing symptoms of moderate to significant discomfort.

“This medication contributes to improved comfort during periods of heightened symptomatic distress and helps maintain a sense of stability when symptoms are more noticeable.”

The therapeutic context is the acute treatment of individual headache episodes, where the medication supports the management of symptoms that become intense or disruptive. For the patient, this provides support that helps ease the overall symptom burden when initial supportive relief is insufficient.

Quick Fact: Support for Tension Headaches (Symptom Complex)

Eligibility and Restrictions for Use

This medication is subject to strict eligibility rules due to its components, codeine (an opioid) and butalbital (a barbiturate), as documented by regulatory bodies like the FDA.

Populations For Whom Use is Contraindicated

The medicine must not be used in the following groups, as per absolute contraindications:

  • Children younger than 12 years of age.
  • Pediatric patients under 18 following surgery for the removal of tonsils and/or adenoids.
  • Individuals with a known hypersensitivity or intolerance to any of its four components (acetaminophen, caffeine, butalbital, or codeine).
  • Patients with a diagnosis of porphyria.
  • Those with significant respiratory depression or acute/severe bronchial asthma in an unmonitored setting.
  • Patients taking Monoamine Oxidase Inhibitors (MAOIs) or who have used them within the past 14 days.

Restricted or Conditional Use

Use requires special caution and close monitoring for certain patients, including the elderly or debilitated, and those with severe renal or hepatic impairment, head injuries, or pre-existing chronic pulmonary diseases. Breastfeeding is not recommended due to the risk of serious adverse reactions in the infant from codeine’s active metabolite, morphine. The medicine is also restricted for individuals known to be CYP2D6 ultra-rapid metabolizers of codeine.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of this medication is derived from the properties of its four active ingredients and is classified according to official regulatory documentation. Co-administration of certain substances is strictly regulated to manage the risk of additive effects and altered drug exposure.

Formal Regulatory Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a formal contraindication. The consumption of Alcohol is also strictly contraindicated due to the severe risk of additive Central Nervous System (CNS) depression combined with the increased potential for Acetaminophen-related hepatotoxicity.

Pharmacodynamic and Pharmacokinetic Interactions

Combinations with other CNS Depressants (including sedatives, general anesthetics, and other opioids) result in documented additive CNS depression. The Codeine component’s metabolism via the CYP2D6 enzyme means that CYP2D6 inhibitors may reduce the formation of its active metabolite, decreasing expected exposure. Conversely, the Butalbital component functions as an inducer of hepatic microsomal enzymes, which may lead to decreased plasma concentrations and reduced therapeutic effect of other concurrently administered medications. Co-administration with CYP2E1 inducers is noted to increase the production of a toxic Acetaminophen metabolite. Interaction severity may be heightened in patients with severe hepatic impairment when co-administered with CYP2E1 inducers, as noted in official labeling.

Mechanism of Action

Fioricet With Codeine exerts its effects through the combined pharmacodynamics of four distinct components within the central nervous system (CNS) and periphery.

Butalbital, a barbiturate, acts as a positive allosteric modulator of the inhibitory GABA A receptor. Binding at the alpha+/beta- interface prolongs the duration of GABA-gated chloride ion channel opening, increasing chloride influx, which hyperpolarizes the postsynaptic neuron. This leads to generalized CNS depression.

Codeine is a prodrug, with its O-demethylated metabolite, morphine, acting as a mathbfmu-opioid receptor agonist primarily in the CNS. Activation of these G-protein coupled receptors inhibits adenylyl cyclase, reducing intracellular cyclic AMP and causing an efflux of potassium ions (hyperpolarization), which ultimately modulates nociceptive signal transmission via descending inhibitory pathways.

Acetaminophen is hypothesized to exert its central effect via inhibition of a cyclooxygenase variant, possibly COX-3, reducing prostaglandin synthesis in the CNS. It may also function through its metabolite AM404 to activate central cannabinoid mathbfCBmathbf1 and TRPV1 receptors, further impacting nociception.

Caffeine acts as a non-selective antagonist of mathbfAmathbf1 and mathbfAmathbf2A adenosine receptors. Blockade of these receptors increases neuronal activity and causes cerebrovascular vasoconstriction.

Dosage and Administration Information

How to Use Fioricet With Codeine

Official Administration Guidelines

The official administration of this fixed-dose combination product is strictly via the oral route as a capsule, typically taken with or without food. The regimen is designated for acute, as-needed (PRN) use and is not intended for scheduled, around-the-clock therapy. The use of the drug is reserved for patients for whom alternative, non-opioid, non-barbiturate treatments have been inadequate.

The standard adult dosing schedule specifies the administration of one to two capsules per dose, taken every 4 hours as needed for symptoms. The regulatory label mandates that the total daily dosage must not exceed 6 capsules in any 24-hour period. Additionally, the total intake of the acetaminophen component from all sources must not exceed 4,000 milligrams per day.

Procedural and Time-Course Constraints

Official guidance is for the use of the lowest effective dosage for the shortest duration consistent with individual goals, as evidence supporting efficacy for multiple recurrent headaches is unavailable. Population-specific rules prohibit the use of this product in children younger than 12 years of age. For older adults, the label advises a cautious approach to dosing, generally suggesting initiation at the low end of the dosing range.

A crucial procedural constraint for patients who are physically dependent is that if discontinuation is necessary, the dose must be tapered gradually rather than stopped abruptly. This formal instruction guides the proper cessation of the medicine.

Recent Clinical Evidence

Fioricet With Codeine: Overview of Clinical Evidence

Fioricet With Codeine is a prescription medication combining butalbital, acetaminophen, caffeine, and codeine phosphate. It is indicated for the management of the symptom complex of tension (or muscle contraction) headache when non-opioid analgesics and alternative treatments are considered inadequate. Due to the presence of butalbital (a barbiturate) and codeine (an opioid), the use of this medication is reserved for acute, limited treatment.


Efficacy in Tension Headache

Clinical trials have examined the combination product's effect in relieving the symptom complex of tension headache. Studies suggest that the combination is associated with statistically significant relief of headache pain when compared to placebo. However, evidence supporting the safety and effectiveness of this specific four-component formulation in the treatment of multiple recurrent or chronic daily headaches is unavailable. The extended use of the combination is not recommended due to risks related to its components.


Research on Component Actions

The actions of the individual components are leveraged in the combination:

  • Butalbital: A barbiturate that causes general central nervous system (CNS) depression, which can affect the perception of discomfort.
  • Acetaminophen: An analgesic component known to raise the pain threshold.
  • Caffeine: A CNS stimulant sometimes included in headache formulations, which is thought to increase the effectiveness of the analgesic agents.
  • Codeine: An opioid component added for pain relief.

Research emphasizes the need to limit use due to the potential for medication-overuse headache and the risk of dependence and withdrawal symptoms associated with both butalbital and codeine.

Frequently Asked Questions (FAQ)

Common questions about Fioricet With Codeine (FAQ)


Q: Is Fioricet With Codeine the same as regular Fioricet?

Fioricet With Codeine is a combination product that contains four active ingredients: butalbital, acetaminophen, caffeine, and codeine phosphate. Regular Fioricet (non-codeine) contains only the first three ingredients. The inclusion of codeine, which is an opioid, places it in a different regulatory classification than the non-opioid product.


Q: How quickly does Fioricet With Codeine usually start working?

Official information regarding the drug's action indicates that the analgesic effect of the codeine component typically reaches its peak concentration within approximately two hours following administration. This timeframe provides an expectation for when the maximum pain relief from that component is typically expected.


Q: What is the expected length of time that Fioricet With Codeine works?

The pain-relieving effects related to the codeine component are described in official documents as persisting for approximately four to six hours.


Q: How is this medicine different from over-the-counter pain relievers?

This medication is formally distinguished from over-the-counter pain relievers because it contains both butalbital (a barbiturate) and codeine (an opioid). Due to these components, regulatory bodies classify it as a Schedule III Controlled Substance, which does not apply to non-prescription products.


Q: Are there certain types of food or drink that interact with it?

Official documents explicitly state that the consumption of alcohol is strictly contraindicated while taking this medicine due to the risk of severe side effects. The product information notes that the medicine can generally be taken with or without food, and there are no comparable restrictions cited for common non-alcoholic beverages.


Q: Is it described as safe to use Fioricet With Codeine during pregnancy?

The official FDA risk summary notes that data are limited regarding the risk of major birth defects or miscarriage. However, official warnings caution that prolonged use of opioids during pregnancy can result in physical dependence in the newborn, leading to Neonatal Opioid Withdrawal Syndrome (NOWS).


Q: Does the medicine lose its effect over time if used regularly?

Official documentation notes that both the butalbital and codeine components may be habit-forming and are associated with the development of physical dependence. The risk profile associated with regular use includes the potential for tolerance, meaning a person may require higher doses to achieve the same effect.


Q: How long after taking the medicine is it described as safe to drive?

Official guidance notes that the drug can cause common adverse reactions like drowsiness, lightheadedness, and dizziness. For this reason, official labeling advises caution regarding driving or operating hazardous machinery, as the effects on alertness may not be immediately clear.


Q: Does Fioricet With Codeine show up on drug tests?

Since the medicine contains codeine (an opioid) and butalbital (a barbiturate), its components are detectable in drug screens. Official information notes that detection windows vary significantly based on the specific type of test used and individual biological factors.


Q: What is the typical timeframe before official bodies recommend reassessing the condition?

Official guidance emphasizes that health providers should check a patient’s progress, particularly within the first 24 to 72 hours of starting treatment. This timeframe is noted in official guidance for the healthcare provider to assess initial progress.


Q: Do studies suggest Fioricet With Codeine helps with migraine headaches?

The official indication for this combination product is limited to the management of the symptom complex of tension (or muscle contraction) headache. It is not formally indicated in regulatory documents for the treatment of migraine headaches.


Q: Can this medication affect blood pressure or heart rate?

Official warnings note that this medication can cause orthostatic hypotension, which is severely low blood pressure when a person changes position. Tachycardia (an increased heart rate) has also been reported as an adverse event in regulatory documents.


Q: Is it common to feel confused or disoriented while using it?

Official adverse reaction reports include both mental confusion and an intoxicated feeling among the reported side effects. Mental confusion may occur particularly in elderly or debilitated patients.


Q: What kinds of symptoms might indicate an official need to seek medical attention immediately?

Symptoms of a serious overdose or adverse reaction requiring immediate medical help include difficult or shallow breathing, pinpoint pupils, or yellowing of the eyes or skin (jaundice, indicating liver problems). Extreme drowsiness or becoming unresponsive are also noted as emergency signs.


Q: Can people with a history of substance use issues use this medication?

Official boxed warnings instruct healthcare providers to assess each patient's risk for addiction, abuse, and misuse prior to prescribing. They must monitor all patients regularly for behaviors or signs of addiction due to the controlled nature of the product.


Q: Are there different strengths of Fioricet With Codeine?

Yes, official labeling indicates that the medicine is manufactured in different strengths. These differences refer to the varied amounts of the codeine phosphate component combined with the other fixed components.


Q: Can this medication cause skin reactions or itching?

Official labeling mentions that rare but serious skin reactions (like Stevens-Johnson Syndrome) may occur due to the acetaminophen component. Pruritus (itching) is also listed as a reported adverse event in official regulatory documentation.

How should Fioricet With Codeine be stored and disposed of?

Official Storage and Disposal Requirements

Fioricet With Codeine capsules, due to their designation as a Controlled Substance, require specific handling for security and stability.

Storage Requirement Official Condition
Temperature Range Controlled Room Temperature: 20 C to 25 C (68 F to 77 F).
Container Rule Keep in original container, ensuring it is tightly closed.
Security Store securely, out of sight and reach of children and pets, and not accessible to others.
Stability Protect from excess heat and moisture, and discard after the expiration date.

Disposal of unused or expired medication must follow official government guidance. The preferred method is taking the capsules to an authorized drug take-back program or a DEA-registered collector. If a take-back program is unavailable, the alternative procedure is to mix the medicine with an unappealing substance, seal it in a plastic bag, and place it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fioricet With Codeine found in:

A-Z Index: